Nina Poetsch
Overview
Explore the profile of Nina Poetsch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
49
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wengert G, Lu H, Aboagye E, Langs G, Poetsch N, Schwartz E, et al.
Eur Radiol
. 2024 Dec;
PMID: 39661150
Objectives: In women with high-grade serous ovarian cancer (HGSOC), a CT-based radiomic prognostic vector (RPV) predicted stromal phenotype and survival after primary surgery. The study's purpose was to fully externally...
2.
Papp L, Rasul S, Spielvogel C, Krajnc D, Poetsch N, Woehrer A, et al.
Front Oncol
. 2023 Feb;
13:986788.
PMID: 36816966
Introduction: Amino-acid positron emission tomography (PET) is a validated metabolic imaging approach for the diagnostic work-up of gliomas. This study aimed to evaluate sex-specific radiomic characteristics of L-[S-methyl-Cmethionine (MET)-PET images...
3.
Krajnc D, Spielvogel C, Grahovac M, Ecsedi B, Rasul S, Poetsch N, et al.
Front Oncol
. 2022 Oct;
12:1017911.
PMID: 36303841
Background: This study proposes machine learning-driven data preparation (MLDP) for optimal data preparation (DP) prior to building prediction models for cancer cohorts. Methods: A collection of well-established DP methods were...
4.
Bartl T, Onoprienko A, Hofstetter G, Mullauer L, Poetsch N, Fuereder T, et al.
Biomolecules
. 2021 Nov;
11(11).
PMID: 34827698
Despite increasing clinical interest in adapting checkpoint inhibitor (CPI) therapies for patients with gynecologic malignancies, no accurate clinical biomarkers to predict therapy response and prognosis are currently available. Therefore, we...
5.
Traub-Weidinger T, Poetsch N, Woehrer A, Klebermass E, Bachnik T, Preusser M, et al.
J Pers Med
. 2021 Jul;
11(7).
PMID: 34209106
Apart from its expression in benign and malignant prostate tissue, prostate specific membrane antigen (PSMA) was shown to be expressed specifically in the neovasculature of solid tumors. For gliomas only...
6.
Huebner N, Korn S, Resch I, Grubmuller B, Gross T, Gale R, et al.
Eur Radiol
. 2020 Dec;
31(6):3754-3764.
PMID: 33263793
Objectives: To assess the visibility of clinically significant prostate cancer (PCA) lesions on the sequences multiparametric MRI of the prostate (mpMRI) and to evaluate whether the addition of dynamic contrast-enhanced...
7.
Beitl K, Rosta K, Poetsch N, Seifried M, Mayrhofer D, Soliman B, et al.
Arch Gynecol Obstet
. 2020 Nov;
303(4):1109-1115.
PMID: 33169235
Purpose: It is still not clear whether to screen women with primary premature ovarian insufficiency for autoimmunity. Moreover, a possible association of autoimmunity with decreased bone mass density in premature...
8.
Poetsch N, Sturdza A, Aust S, Polterauer S, Grimm C, Schwameis R, et al.
Strahlenther Onkol
. 2019 Feb;
195(5):430-440.
PMID: 30737542
Background: Deficiency in butyrylcholinesterase (BChE), a condition commonly noticed in liver damage, inflammation, and malnutrition, has previously been associated with impaired prognosis in different malignancies. The aim of the present...
9.
Poetsch N, Woehrer A, Gesperger J, Furtner J, Haug A, Wilhelm D, et al.
Neuro Oncol
. 2017 Oct;
20(3):411-419.
PMID: 29016947
Background: Few data exist regarding the prognostic value of L-[S-methyl-11C]methionine (MET) PET for treatment-naïve gliomas. Methods: A total of 160 glioma patients (89 men, 71 women; mean age: 45, range...